Medeor Therapeutics
Medeor Therapeutics is dedicated to improving transplant outcomes by developing innovative immunotherapies that enable long-lasting immune tolerance, potentially eliminating the need for lifelong immunosuppressant drugs. With a platform based on 20 years of research from Stanford University, the company focuses on creating cellular therapies that induce mixed chimerism, promoting immune acceptance of transplanted organs and treating hematological diseases. Currently in Phase 3 clinical trials, Medeor aims to transform transplant medicine and address unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Medeor Therapeutics
611 Gateway Blvd. Suite 120, South San Francisco, CA 94080
Patents
Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
US-11819521-B2
View DetailsCellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
US-11813376-B2
View DetailsCompositions for establishing mixed chimerism and methods of manufacture thereof
US-11701392-B2
View DetailsCompositions for establishing mixed chimerism and methods of manufacture thereof
US-10881692-B2
View Details
Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
US-11819521-B2
View DetailsCellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
US-11813376-B2
View DetailsCompositions for establishing mixed chimerism and methods of manufacture thereof
US-11701392-B2
View DetailsCompositions for establishing mixed chimerism and methods of manufacture thereof
US-10881692-B2
View DetailsProducts
Cellular immunotherapy candidate for induction of transplant tolerance (HLA-matched living-donor kidney)
A patient-specific donor/recipient cellular product designed to induce mixed chimerism and donor-specific immune tolerance following a single-dose infusion; developed through Phase 3 for HLA-matched living-donor kidney transplant recipients.
Cellular immunotherapy candidates for mismatched and delayed-tolerance transplant protocols
Pipeline candidates developed to induce mixed chimerism in HLA-mismatched living-donor kidney transplants and delayed-tolerance protocols (Phase 2), using similar donor/recipient cell approaches.
Hematology program candidates (including sickle cell disease IND-stage program)
Programs applying mixed-chimerism approaches to hematologic and potentially oncologic indications; includes at least one IND-stage program for sickle cell disease.
Cellular immunotherapy candidate for induction of transplant tolerance (HLA-matched living-donor kidney)
A patient-specific donor/recipient cellular product designed to induce mixed chimerism and donor-specific immune tolerance following a single-dose infusion; developed through Phase 3 for HLA-matched living-donor kidney transplant recipients.
Cellular immunotherapy candidates for mismatched and delayed-tolerance transplant protocols
Pipeline candidates developed to induce mixed chimerism in HLA-mismatched living-donor kidney transplants and delayed-tolerance protocols (Phase 2), using similar donor/recipient cell approaches.
Hematology program candidates (including sickle cell disease IND-stage program)
Programs applying mixed-chimerism approaches to hematologic and potentially oncologic indications; includes at least one IND-stage program for sickle cell disease.
Services
End-to-end clinical development services for cell-based transplant tolerance programs, including protocol design, trial execution, outcomes monitoring, and regulatory engagement.
Provision of educational materials and resources for patients and treating physicians about investigational cell-therapy options and clinical-trial participation.
End-to-end clinical development services for cell-based transplant tolerance programs, including protocol design, trial execution, outcomes monitoring, and regulatory engagement.
Provision of educational materials and resources for patients and treating physicians about investigational cell-therapy options and clinical-trial participation.
Expertise Areas
- Clinical trial management for transplant immunotherapies (Phase 1–3)
- Cellular immunotherapy development
- Mixed chimerism and transplant tolerance
- Transplant immunology and conditioning protocols
Key Technologies
- Mixed-chimerism cell therapy
- Hematopoietic stem/progenitor cell (CD34+) transplantation
- T-cell (CD3+) based immunomodulation
- Single-dose donor/recipient cell infusion
News & Updates
A virtual symposium discussing advances in organ transplant cell therapy to induce donor-specific immune tolerance and avoid rejection, scheduled for June 17, 2021.
A scientific publication in Science Translational Medicine reviewing the role of mixed chimerism in transplant tolerance.
A review article in Human Immunology discussing different approaches to achieve immune tolerance through chimerism.
A broad review of immune tolerance in organ transplant published in Cold Spring Harbor Perspectives in Medicine.
Phase 3 Clinical Trial in Kidney Transplantation
Medeor has completed a pivotal Phase 3 clinical trial demonstrating the potential to induce immune tolerance and eliminate the need for lifelong immunosuppressants in HLA-matched kidney transplant recipients.
Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA
MDR-101 received RMAT designation from the FDA, recognizing its potential to treat serious conditions and expedite development.
A virtual symposium discussing advances in organ transplant cell therapy to induce donor-specific immune tolerance and avoid rejection, scheduled for June 17, 2021.
A scientific publication in Science Translational Medicine reviewing the role of mixed chimerism in transplant tolerance.
A review article in Human Immunology discussing different approaches to achieve immune tolerance through chimerism.
A broad review of immune tolerance in organ transplant published in Cold Spring Harbor Perspectives in Medicine.
Phase 3 Clinical Trial in Kidney Transplantation
Medeor has completed a pivotal Phase 3 clinical trial demonstrating the potential to induce immune tolerance and eliminate the need for lifelong immunosuppressants in HLA-matched kidney transplant recipients.
Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA
MDR-101 received RMAT designation from the FDA, recognizing its potential to treat serious conditions and expedite development.